期刊文献+

Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA:a subgroup analysis of the CHANCE trial 被引量:7

原文传递
导出
摘要 Objective Many patients receiving dual antiplatelet therapy still had recurrent strokes.We aimed to identify factors associated with recurrent stroke at 90 days in patients receiving dual antiplatelet therapy in Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events trial.Methods Patients with transient ischaemic attack or minor stroke receiving clopidogrel and aspirin in the trial were analysed in the study.The primary outcome was recurrent stroke within 90 days after the index event.Cox proportional hazard model with backward selection was used to identify factors associated with stroke.results Among 2584 patients,212(8.2%)had a recurrent stroke,216(8.4%)had a composite of stroke,myocardial infarction,or vascular death and 204(7.9%)had ischaemic stroke within 90 days.Multivariate analysis identified the following factors associated with stroke:history of hypertension with poor blood pressure control(HR,1.92;95%CI 1.22 to 3.03),the high baseline National Institute of Health Stroke Scale(NIHSS)score of 2 and 3(2.12(1.07 to 4.21)and 4.11(2.05 to 8.22),respectively),time from onset to randomisation of<12 hours(1.47(1.12 to 1.94)),the lipid-lowering therapy(0.61(0.47 to 0.83)),the open-label aspirin dose at day 1 of≥300 mg(1.98(1.45 to 2.69)).Intracranial arterial stenosis(ICAS)was significantly associated with stroke in the sensitivity analysis(2.17(1.16 to 4.04)).conclusions The high baseline NIHSS score,hypertension with poor blood pressure control,ICAS,time from onset to randomisation of less than 12 hours and no lipid-lowering therapy were associated with stroke,suggesting that patients with identified predictors still remain to be at high risk of recurrent stroke although being under the dual antiplatelet therapy.
出处 《Stroke & Vascular Neurology》 SCIE 2017年第4期176-183,共8页 卒中与血管神经病学(英文)
基金 The study was supported by grants from the Ministry of Science and Technology of the People’s Republic of China and Program for New Century Excellent Talents in University.The grant numbers are 2008ZX09312-008,2011BAI08B02,2012ZX09303,200902004 and NCET-13-0917.
关键词 PATIENTS Acute analysis
  • 相关文献

参考文献2

二级参考文献99

  • 1Wahlgren N, Ahrced N, Davalos A, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet, 2007, 369: 275-282.
  • 2Lyden PD, ed. Thrombolytic Therapy for Acute Stroke. 2nd ed. Totowa, NJ: Hmreana Press, 2005.
  • 3Wardlaw JM, Smdercock PA, Berg: E. Throrrbolytic therapy with recoinbinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cunaflative meta-analysis. Stroke, 2003, 34: 1437-1442.
  • 4Wardlaw JM, Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev, 2003, (4): CD000213.
  • 5Shanna M, Clark H, Armour T, et al. Acute stroke: evaluation and treatment. Evid Rep Technol Assess (Sunmm), 2005, (127): 1-7.
  • 6Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Throrrbolysis for acute ischemic stroke: results of the Canadian Altephse for Stroke Effectiveness Study. CMAJ, 20(0, 172: 1307-1312.
  • 7Chung H, Refoios Canto R, Canto RR, et al. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart, 2007, 93: 1616-1617.
  • 8Saver JL, Smith EE, Fonarow GC, et al; GWTG-stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in > 30,000 patients ariving within 60 minutes of stroke onset. Stroke, 2010, 41: 1431-1439.
  • 9Scott PA, Xu Z, Meurer WJ, et al. Attitudes and beliefs of Michigan emergmcy physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke, 2010, 41: 2026-2032.
  • 10Kwiatkowski TG, Libman RB, Fmnkel M, et al. Effects of tissue plasrrfinogen activator for acute ischemic stroke at one year. National Institute of Neurological Disordeis and Stroke Recombinxaat Tissue Plasmiogen Activator Stroke Study Group. N Engl J Med, 1999, 340: 1781-1787.

共引文献984

同被引文献29

引证文献7

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部